
Nanobiotix SA (NBTX) Stock Forecast & Price Target
Nanobiotix SA (NBTX) Analyst Ratings
Bulls say
Nanobiotix is viewed favorably because its lead asset NBTXR3 has already shown clinical proof-of-concept in Phase 1/2 studies, including a more than doubling of pathological complete response in soft tissue sarcoma versus radiation alone, while also benefiting from a 2023 partnership that transferred global rights and brought up to $1.8Bn in milestones plus tiered royalties. Its first pivotal catalyst, NANORAY-312 in chemo-ineligible LA-HNSCC, is considered high probability of success and could validate a tumor-agnostic, physics-based mechanism that fits seamlessly into existing radiotherapy practice, with supportive data also emerging in Stage III NSCLC through CONVERGE. Financially, the company ended 1Q26 with €42.1M in cash and equivalents and a runway into 2029, reducing near-term funding risk while it advances multiple large-market opportunities.
Bears say
Nanobiotix is exposed to substantial clinical, regulatory, commercial, and intellectual property risk, with a high likelihood that trial failures, safety concerns, or regulatory setbacks could derail value creation across its novel pipeline. The company also faces execution and financial strain, as meaningful debt on the balance sheet and the need for additional funding before turning cash flow positive raise the risk of potentially dilutive financing and spending overruns. Further, the outlook is weakened by uncertainty around undisclosed collaboration milestones and the possibility that post-approval commercial performance falls below expectations, especially for a highly novel lead program that may face logistical challenges.
This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.
Nanobiotix SA (NBTX) Analyst Forecast & Price Prediction
Start investing in Nanobiotix SA (NBTX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Nanobiotix SA (NBTX) Forecast
Nanobiotix SA (NBTX) Analyst Forecast & Price Prediction
Start investing in Nanobiotix SA (NBTX)
Order type
Buy in
Order amount
Est. shares
0 shares